Live feed
·
PRReleasevia Quantisnow
Nasus Pharma Ltd. logo

Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen® with Accelerated Speed to Therapeutic Threshold

ByQuantisnow·Wall Street's wire, on your screen.
NSRX· Nasus Pharma Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NSRX (Nasus Pharma Ltd.) and more on Quantisnow.